1.Core Information

　　The Department of Endocrinology and Metabolism at Shenzhen Third People's Hospital led the establishment of the Endocrinology and Metabolism Discipline Alliance, which covers 24 hospitals and community health centers across Longgang, Luohu, Yantian, and Pingshan Districts, promoting regional improvements in the diagnosis and treatment of endocrine and metabolic diseases as well as translational medicine research. The department has been approved as a standing member unit of the Guangdong Medical Association and the chairman unit of the Shenzhen Physician Association Diabetes Special Committee.

　　The department currently operates multiple specialist outpatient clinics and independent inpatient wards, staffed by a total of 26 medical professionals, including 11 doctors and 15 nurses. The current academic team includes three senior titles, seven intermediate titles, one postdoctoral supervisor, two Ph.D. holders, nine master's degree holders, and two professionals who have studied abroad as visiting scholars. Additionally, the team comprises one doctoral supervisor, one Shenzhen Elite Talent, one Shenzhen Special Appointed Talent, and one National Natural Science Foundation review expert. There are three specialist nurses, including one diabetes education nurse, one diabetes specialist nurse, and one diabetic foot specialist nurse.

　　2.Clinical Services

• Diabetes and Its Complications: Point-of-care blood glucose testing, integrated inpatient-outpatient remote management system for hyperglycemia, insulin pump therapy, vibration perception threshold (VPT) testing, continuous glucose monitoring (CGM) system, subcutaneous fat analyzer, diabetic foot wound healing promotion.

• Thyroid Disorders (Hyperthyroidism, Hypothyroidism, Thyroid Nodules, Thyroiditis, Thyroid-Associated Ophthalmopathy)

• Obesity

• Adrenal Disorders (Adrenal Tumors, Primary Aldosteronism, Cushing’s Syndrome, Pheochromocytoma)

• Pituitary Tumors

• Osteoporosis

• Disorders of Sexual Development

• Hyperuricemia

• Polycystic Ovary Syndrome (PCOS)

　　3.Special Features & Advantages

• multidisciplinary team

　　Focusing on the diagnosis and treatment of complex endocrine disorders, our department leverages the Multidisciplinary Team (MDT) model as a core strategy. By integrating resources across the hospital, we have established five specialized MDT teams targeting Diabetes Remission/Reversal, Weight Management for Overweight/Obesity, Thyroid-Associated Ophthalmopathy, Diabetic Painful Neuropathy, and Neuroendocrine Tumors. Through regular joint discussions involving endocrinologists,, ophthalmologists, neurologists, pathologists, and other relevant specialists, we develop individualized, whole-course treatment plans for each patient. This patient-centered collaborative approach breaks down traditional specialty barriers, significantly enhancing both the efficiency and clinical outcomes of managing complex endocrine diseases, ensuring that patients with difficult conditions have access to top-tier integrated care close to home.

• In-Hospital and Out-of-Hospital" intelligent management platform for hyperglycemia.

　　By introducing Continuous Glucose Monitoring (CGM) technology, we replace traditional fingertip blood tests to achieve continuous visualization of glucose profiles. Through the in-hospital and out-of-hospital glucose management system, patient data is synchronized in real-time to medical terminals, enabling physicians to remotely monitor glucose fluctuations and provide timely intervention guidance, whether the patient is in the ward or at home. This model breaks the time and space constraints of glucose management, significantly reducing the risk of hypoglycemia during hospitalization while providing long-term remote care for discharged patients, effectively improving glycemic control rates and reducing readmissions. We are committed to creating a complete closed-loop management system from hospital to home, allowing patients to truly benefit from convenient and precise smart healthcare.

　　4.Education & Research

　　Master’s degree training site for Southern University of Science and Technology, Shenzhen University, and Shantou University; responsible for standardized training tasks in Shenzhen for general practice and internal medicine; and responsible for整班 teaching for undergraduates at Hubei University of Medicine.

• Wang Q, Zhang Z, Chai Q, Shan Y, Lu D, Chen Y, Liu M, Wu W*. Correlation Between Retinopathy and Coronary Microcirculation Dysfunction in Patients with Type 2 Diabetes Mellitus. Eur J Ophthalmol. 2022 Sep;32(5):2857-2863. （Q4；IF 1.7）

• Wu W*, Chai Q, Zhang Z. Inhibition of SGLT1 Alleviates the Glycemic Variability-Induced CardiacFibrosis via Inhibition of Activation of Macrophage and Cardiac Fibroblasts. Mol Cell Biol. 2022 Feb 17;42(2):e0028221. （Q2；IF 5.3）

• Zhang Z, Chen Y, Wang Q, Xie L, Shan Y, Yang N, Wu W*. Influence of fasting plasma glucose-lowering rate on BNP levels in type 2 diabetes mellitus patients with coronary microcirculation dysfunction. Hormones (Athens). 2023 Mar;22(1):33-43. （Q3；IF 3.2）

• Wang Q， Xie L，Lu D， Chen Y， Shan Y， Wu W*，nfluence of fluctuations in fasting blood glucose on left ventricular function in patients with type 2 diabetes mellitus and coronary microcirculation dysfunction: a prospective cohort study. Acta Diabetol. 2025 Oct;62(10):1761-1773. （JCR Q2，IF=3.1）

• Zhang Y, Peng W, Huang J, Zhang W, Jiang P, He Y, Wang M. Causal Associations of Iron Status With the Renal Function and Diabetic Nephropathy in Patients With Diabetes Mellitus: A Two-Sample Mendelian Randomization Study. J Diabetes Res. 2025 Jul 30;2025:6658794. （JCR Q2，IF=3.6）

• Mechanistic Study of Blood Glucose Fluctuation-Induced Pyroptosis in Diabetic Cardiomyopathy via SGLT-1 Targeting and the NLRP3 Signaling Pathway*; Principal Investigator, General Program of National Natural Science Foundation of China (RMB 570,000); 2019.01 – 2022.12.

• Impact of Changes in Visceral Fat Area on Pancreatic Beta-Cell Function in Patients with Type 2 Diabetes Mellitus*; Principal Investigator, 2022 Hospital-Level Clinical Project of Luohu District People's Hospital (RMB 300,000); 2023.01.01 – 2025.12.31.

• Impact of Changes in Visceral Fat Area on Pancreatic Beta-Cell Function in Patients with Type 2 Diabetes Mellitus* (Grant No. YXJL-2023-0314-0229); Principal Investigator, Beijing Medical Award Foundation (RMB 50,000); 2023.11.01 – 2025.10.31.

• Correlation Study of Blood Glucose Fluctuation with Cardiac Autonomic Neuropathy and Cardiac Function in Patients with Type 2 Diabetes Mellitus (Grant No. 24-HX-19); Principal Investigator, Research Project of the Guangdong Health Economics Association (RMB 30,000); 2024.12.01 – 2027.11.01.

• Study on the Necessity of Additional Hepatoprotective Therapy for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Injury under MDT Team Management: A Single-Center, Single-Blind, Randomized Controlled Trial on Bicyclol; Hospital-Level Clinical Project, Shenzhen Third People's Hospital (Grant No. 25270G1008); Principal Investigator, Internal Supporting Project for Discipline Construction, Shenzhen Third People's Hospital (RMB 500,000); 2025.01 – 2027.12.

• Molecular Mechanism of Glycogen Deposition Aggravating Diabetic Cardiomyopathy Induced by Glycemic Variability via the NAK1/SLC5A1 Signaling Pathway: Insights from Glycophagy*; Principal Investigator, National Natural Science Foundation of China Incubation Project, Shenzhen Third People's Hospital (RMB 150,000); 2026.01.01 – 2027.12.31.

• Exploring the Application of Peer Education in Clinical Internships for Medical Undergraduates" was recognized as an achievement of the Teaching Reform Research Project of the Health Science Center, Shenzhen University, in February 2025.

• 《Research on the Application of the MDT Combined with CBL Teaching Model Based on the OBE Concept in Undergraduate Internal Medicine Teaching" – A project approved by the Department of Education of Guangdong Province for 2025 (Project Initiation).